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Abstract
Over the past two decades, considerable progress in technology and clinical research methods have
led to advances in the diagnosis, treatment and prevention of acute venous thromboembolism.
Despite this, however, the diagnosis is still often missed and preventive methods are often ignored.
Published guidelines are useful, but are limited by the existing evidence base so that controversies
remain with regard to topics such as duration of anticoagulation, indications for placement and
removal of inferior vena caval filters, and when and how to administer thrombolytic therapy. The
morbidity and mortality of this disease remain high, particularly when undiagnosed. While preventive
approaches remain crucial, the focus of this review is on the diagnostic and therapeutic approach to
acute venous thromboembolism, with an emphasis on acute pulmonary embolism.
Introduction
Venous thromboembolism includes the spectrum of
deep venous thrombosis and pulmonary embolism.
Acute pulmonary embolism is a worldwide problem
responsible for 100,000 to 300,000 deaths per year in
the United States alone [1-3], and it is commonly not
diagnosed or even suspected until after the patient dies
[4,5]. There should be a strong clinical suspicion of
pulmonary embolism in settings with compatible
symptoms (such as dyspnea and chest pain), particularly
when risk factors are present. Unfortunately, in patients
who die of acute pulmonary embolism, the clinical
presentation is often atypical,making the diagnosis more
challenging [5]. Therapy should be initiated and diag-
nostic testing undertaken when the disease is suspected
[1,6]. This review will focus on the diagnostic and
therapeutic approach to acute pulmonary embolism.
Pathophysiology of acute pulmonary embolism
The vast majority (95%) of acute pulmonary embolism
cases originate from thrombi in the leg or pelvic veins,
althoughembolimayarisefromothersourcessuchasthe
axillary subclavian system or the renal veins [6]. Death
from acute pulmonary embolism is caused by right
ventricular failure. When thrombosis propagates from
the calf veins to the larger more proximal veins, or
originates more proximally, the likelihood of emboliza-
tion, as well as the impact on the lungs, increases. As
the embolic burden increases, right ventricular afterload
increases and there is right ventricular dilation and
hypokinesis associated with the increased pulmonary
vascular resistance. When the clot burden reaches a
critical threshold, the right ventricle is unable to generate
enough force to achieve an adequate cardiac output and
fails,resultinginhypotensionandcardiacarrest.Acrucial
issue in acute pulmonary embolism is how to risk-stratify
patients; i.e. how we translate the status of the patient,
and particularly the right ventricle, into meaningful
treatment decisions.
Risk factors and diagnostic approach
Idiopathic venous thromboembolism occurs, but most
patients have one or more underlying risk factors
arising from Virchow’s triad of stasis, venous injury, or
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When suspected, patients should undergo diagnostic
testing and if there is a high clinical suspicion and low
perceived risk of bleeding, therapy should be initiated
during the diagnostic evaluation [1,6,8]. The spectrum of
pulmonary embolism presentations ranges from asymp-
tomatic/minimal symptoms to massive emboli causing
sudden death or progressing rapidly to death from right-
heart failure.
Dyspnea and chest pain are the most common symptoms
ofacute pulmonaryembolism;these and other symptoms
and signs are nonspecific (Table 2). While pulmonary
embolism commonly presents with symptoms of sudden
onset, as many as 25% of patients with proven acute
pulmonary embolism relatetheir onset oftheir symptoms
at more than two weeks prior to the time of diagnosis [9].
Contrary to popular teaching, chest wall tenderness can
occur in acute pulmonary embolism because of pulmon-
ary infarction [10]. Patients with acute pulmonary embo-
lism may have no symptoms from the emboli; incidental
pulmonary embolism is sometimes documented by com-
puted tomographic angiography (CTA) [6]. It is clear that,
with improving technology, multidetector CTA is detect-
ing small, often asymptomatic emboli in patients under-
goingCTAforanotherreason.Whileitisnotclearwhether
all such patients require therapy, the standard approach at
present is to treat [1]. Alarmingly, however, one recent
study suggested that cancer patients diagnosed with and
treated for incidentalpulmonaryembolism have thesame
high rates of recurrent venous thromboembolism, bleed-
ing complications, and mortality, as those who develop
symptomatic pulmonary embolism [11].
Ancillary diagnostic testing
Laboratory testing cannot rule pulmonary embolism in
with certainty [6,8]. Leukocytosis is much more common
with infection than with pulmonary embolism; in one
study, among patients with pulmonary embolism in
whom other possible or defined causes for leukocytosis
were eliminated, 52 of 266 (20%) had a white blood
cell count > 10,000/mm
3 [12]. D-dimer testing is a very
sensitive measurement of fibrinolytic activity but not
specific enough to be diagnostic of pulmonary embolism
[13]. The D-dimer assay is best utilized in patients with
low or moderate clinical probability, and clinical
probability models of D-dimer levels have been designed
and validated. Increasing D-dimer levels do appear to
correlate with increasing mortality [14]. Serum troponin
may be positive in acute pulmonary embolism, indicat-
ing right ventricular ischemia / microinfarction [15] and
this is discussed further under “Risk stratification” below.
Brain natriuretic peptide (BNP) levels may also be
elevated in acute pulmonary embolism because of right
ventricular dilation [16]. This may serve as a clue to the
diagnosis, but again is nonspecific.
Arterial blood gas analysis may demonstrate hypoxemia
and hypocapnia (decreased PCO2) but may also be
normal, particularly in younger patients without cardio-
pulmonarydisease[17].Inthesettingofanormalornear-
normal chest radiograph and significant unexplained
hypoxemia, pulmonary embolism should be considered.
The electrocardiogram is nonspecific in acute pulmonary
embolism [18]. It may be normal, or may demonstrate
sinus tachycardia or an atrial arrhythmia. In particular,
new-onset atrial flutter should increase suspicion of acute
Table 1. Risk factors for Venous Thromboembolism*
Hereditary factors** Acquired factors* Probable factors
Antithrombin deficiency Reduced mobility Elevated homocysteine
Protein C deficiency Advanced age Elevated factors VIII, IX, XI
Protein S deficiency Cancer Elevated fibrinogen
Factor V Leiden Acute medical illness Elevated thrombin-activated fibrinolysis inhibitor
Activated protein C resistance without
factor V Leiden
Pregnancy and the postpartum period Low levels of tissue factor pathway inhibitor
Prothrombin gene mutation Trauma
Plasminogen deficiency Spinal cord injury
Dysfibrinogenemia Major surgery
Oral contraceptives
Hormone replacement therapy
Polycythemia vera
Antiphospholipid antibody syndrome
Heparins
Chemotherapy
Obesity
Central venous catheterization
Immobilizer or cast
*In a compatible clinical setting, acute deep venous thrombosis and/or pulmonary embolism should be considered even in the absence of known risk factors.
**It remains unclear whether some of the disorders listed above are hereditary, acquired, or both.
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present onthe electrocardiogram,but againisnonspecific.
With extensive emboli, a right ventricular strain pattern
m a yb ep r e s e n t ,w h i c hc a na l s ob ec o n s i d e r e dw i t hr e g a r d
to determining the level of aggressiveness for therapy in
proven pulmonary embolism (also see “Risk stratification
in acute pulmonary embolism” below).
The chest radiograph is often abnormal in acute
pulmonary embolism, but may be normal or minimally
abnormal [20]. Pulmonary infarction may be associated
with pleural-based wedge-shaped infiltrates (Hampton’s
hump), which may be mistaken for pneumonia, and
reduced lung markings associated with an ipsilateral
prominent proximal pulmonary artery (Westermark
sign) may suggest acute pulmonary embolism. Impor-
tantly, echocardiography may identify emboli in-transit
in the right atrium and may indicate the diagnosis prior
to lung imaging, but this is somewhat unusual, so
echocardiography is best used in suspected or proven
acute pulmonary embolism to assess the impact of
acute pulmonary embolism on right ventricular function.
“McConnell’ss i g n ” (a regional pattern of right ventricular
dysfunction, with akinesia ofthe mid free wall rightventri-
cular free wall but normal apical contractility) can occur in
pulmonaryembolism,butacuterightventricularinfarction
may cause a similar appearance [21].
When pulmonary embolism is suspected, the history and
risk factors, physical exam, and ancillary studies should be
integrated to form a differential diagnosis and determine
the need for specific testing for acute pulmonary embo-
lism. Formulation of a pretest probability can facilitate the
clinician’s approach. This can be done simply by gestalt,
relying on the clinician’s experience, comfort level with
the disease, and knowledge of the pulmonary embolism
literature. However, increasing data support the use of
clinical prediction models to guide the diagnostic
approach. The most widely studied models include the
Wells score [13], the PERC score [22], and the series of
Geneva scores [23-25] (Tables 3a-c). While these models
have clear utility, a strong clinical suspicion of acute pul-
monary embolism should not be ignored solely because a
clinical predictive model suggests that it can be.
Diagnostic imaging for suspected
pulmonary embolism
In patients presenting with suspected acute pulmonary
embolism, CTA has become the standard diagnostic test
in the United States. Echocardiography may establish the
diagnosis in certain settings, such as when emboli in-
transit are visualized in the right atrium.
A normal VQ (ventilation/perfusion) scan rules out
pulmonary embolism, and a high probability VQ scan in
thesettingof suspectedpulmonaryembolismisessentially
diagnostic [26]. However, in the majority of patients with
acute pulmonary embolism, VQ scans are not diagnostic
[26]. Strong clinical suspicion of pulmonary embolism in
the setting of a nondiagnostic VQ scan should lead to
another imaging study (CTA, pulmonary angiography, or
leg imaging). Ideal candidates with suspected pulmonary
embolism to consider for VQ scanning would be younger
patients, generally under age 40, without underlying
cardiopulmonary disease.
A good quality CTA that is negative for acute pulmonary
embolism essentially rulesoutthediagnosisandspecificity
is excellent [27]. CTA is also very useful in demonstrating
other potential causes of dyspnea and chest pain. In
addition, CTA may prove that pulmonary embolism is
present when another diagnosis initially appears more
Table 2. Symptoms and Signs in Patients with Acute Pulmonary Embolism Without Preexisting Cardiopulmonary Disease
Symptoms Patients (%) Signs Patients (%)
Dyspnea 73 Tachypnea (respiratory rate ≥20 breaths/min) 70
Pleuritic pain 66 Rales/crackles 51
Cough 37 Tachycardia (heart rate >100 beats/min) 30
Leg swelling 28 Fourth heart sound 24
Leg pain 26 Increased pulmonary component of second sound 23
Hemoptysis 13 DVT 11
Palpitations 10 Diaphoresis 11
Wheezing 9 Temperature >38.5°C 7
Angina-like pain 4 Wheezes 5
Homans’ sign 4
Right ventricular lift 4
Pleural friction rub 3
Third heart sound 3
Cyanosis 1
DVT, deep venous thrombosis.
Adapted from Stein PD, Terrin ML, Hales CA, et al. [17].
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that there was a 25% prevalence of pulmonary embolism
in patients with COPD (chronic obstructive pulmonary
disorder) hospitalized for what was felt to be a COPD
exacerbation [28]. Multidetector CTA is quitesensitive, but
small, subsegmental emboli are still sometimes difficult to
visualize. If a study is suboptimal or if there is doubt,
additional lung or leg imaging should be considered.
Imaging of the leg veins by computed tomographic
venography can be performed to establish the diagnosis
of concomitant deep venous thrombosis, or to look for
deep venous thrombosis when the chest CTA is negative,
but of course this increases radiation exposure for the
patient[29].Recentdatasuggestthatmortalityduetoacute
pulmonary embolism is higher in the setting of residual
deepvenousthrombosis,sothatevaluatingthelegsinacute
pulmonary embolism may become more common [30].
While pulmonary angiography has been the gold-
standard for establishing the diagnosis of acute pulmon-
ary embolism for decades, it is rarely done nowadays
[31]. However, an advantage of this technique is the
ability to also consider more aggressive catheter-directed
techniques in the setting of extensive emboli (see section
on treatment below).
Magnetic resonance angiography takes more time to
complete than CTA and the diagnostic yield for
pulmonary embolism has been shown to be institution
dependent [30]. With nephrogenic fibrosing dermopa-
thy in the setting of renal insufficiency, enthusiasm has
Table 3. Criteria for the Wells, PERC and revised Geneva score
Table Feature Points
3a. The Wells Score* PE is most likely diagnosis Yes = 3 points
Symptoms and signs of DVT present Yes = 3 points
Heart rate > 100/minute Yes = 1.5 points
Immobilization at least 3 days, or surgery in previous 4 weeks Yes = 1.5 points
Previous, objectively diagnosed DVT or PE Yes = 1 point
Hemoptysis Yes = 1 point
Malignancy with treatment within 6 months Yes = 1 point
3b. The PERC Score** Age < 50 years
Pulse < 100/minute
Oxygen saturation > 94%
Absence of unilateral leg swelling
Absence of Hemoptysis
Recent surgery
Prior DVT/PE
Oral contraceptive use
3c. Revised Geneva score
† Age > 65 years 1
Previous DVT or PE 3
Surgery or fracture within 1 month 2
Active malignancy 2
Hemoptysis 2
Heart rate 75 to 94/minute 3
Heart rate > 95/minute 5
Unilateral lower limb pain 3
Pain on deep palpation of lower limb and unilateral edema 4
0-3 points low probability for acute pulmonary embolism (8%)
4-10 points = intermediate probability (28%)
>11 points = high probability (74%)
*In the validation cohort, a score < 4.0 (PE unlikely) combined with a negative Simpli-Red D-dimer assay (not an ELISA-based assay) accurately excluded
a diagnosis of acute PE in 98% of patients. As per the first 3 point item in the score, gestalt is part of the method; it is not entirely objective. Furthermore,
it has been suggested that, commonly, this subjective 3 point “PE most likely” is what tips the score in favor of PE [13].
**The PERC rule was designed to rule out acute PE in patients presenting to the emergency room without further testing. The 8 variables are listed above.
As a diagnostic test, low suspicion and PERC negative status has been shown to have a sensitivity of 97.4% (CI 95.8% to 98.5%) and specificity of 21.9%
(CI 21.0% to 22.9%) [22].
†The Geneva score was originally designed as a somewhat complex clinical prediction rule which required arterial blood gas analysis. It was ultimately
revised, only including clinical data. It was more recently simplified. There are similarities to the Wells score and a recent study suggests that the Wells rule
may be more accurate among inpatients and patients presenting to the emergency department, while the revised Geneva score can be used in the
emergency department with high reliability.
The simplified Geneva score includes the same parameters as the revised score but the score for each parameter is uniformly 1 point, and if heart rate is
> 95/minute an additional point was added. It is suggested that the likelihood of patients having PE with a simplified Geneva score < 2 and a normal D-dimer is
3% [23-25].  Abbreviations:  PE,  pulmonary  embolism;  DVT,  deep  vein thrombosis 
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thrombosis. However, ultrasound is simpler, faster, and
adequate in the majority of cases of suspected acute deep
venous thrombosis. If chest imaging cannot be per-
formed, ultrasound of the legs can be performed. If deep
venous thrombosis is ruled in, the need for therapy is
established. [6,32].
In summary, the diagnosis of acute pulmonary embo-
lism requires an integrated approach, often involving
more than one test and at least one imaging modality.
Prediction rules continue to evolve.
Treatment of acute pulmonary embolism
The primary goal of treatment in venous thromboem-
bolism is the prevention of thrombus extension and
pulmonary embolism. The therapeutic approach is
generally the same for deep venous thrombosis and
pulmonary embolism [1].
Initial therapy – anticoagulation
Pulmonary embolism patientswithstable hemodynamics
appear to have a low death rate when anticoagulated,
provided they have no major underlying disease. Thus,
such individuals are treated with either low molecular
weight heparin or unfractionated heparin [1]. Impor-
tantly, anticoagulation should be considered even prior to
the diagnosis of pulmonary embolism if the clinical
suspicion is high and the risk of bleeding deemed low [1].
TheAmericanCollegeofChestPhysicians(ACCP)consen-
sus statement on venous thromboembolism recommends
subcutaneous low molecular weight heparin over stan-
dard,unfractionatedheparin[1].Ifunfractionatedheparin
is used, the bolus and intravenous drip should be weight-
based. Table 4 lists advantages of low molecular weight
heparin. Once-daily, subcutaneous fondaparinux with-
out monitoring is at least as effective and as safe as
intravenousunfractionatedheparinintheinitialtreatment
of patients with stable acute pulmonary embolism [33],
and has similar advantagesover unfractionated heparin as
low molecular weight heparin, though renal insufficiency
(creatinine clearance < 30 mL/min) is a contraindication.
While long-term therapy is beyond our scope, recommen-
dations on duration of anticoagulation are outlined in the
ACCP statement [1].
The development of new oral agents for both initial and
long-term treatment is likely to ultimately simplify the-
rapy [34]. Direct factor Xa inhibitors, such as rivaroxaban
and apixaban target an upstream protease in the clotting
cascade, and represent a promising approach in antic-
oagulation [35-37]. Rivaroxaban and apixaban have
recently been approved (in the USA and the E.U.
respectively), both are approved for venous thromboem-
bolism prophylaxis in total hip and knee replacement but
not for therapy of established acute venous thromboem-
bolism. The results of the EINSTEIN deep venous
thrombosis and EINSTEIN EXT studies indicate that
rivaroxaban offers an improved risk-benefit profile for
acute deep venous thrombosis and is a promising
alternative to enoxaparin or oral warfarin [38], and the
latter study is ongoing [39]. Dabigatran is a direct
thrombin inhibitor that is approved by the FDA for
prevention of stroke and blood clots in patients with
nonvalvular atrial fibrillation [40,41]. Clinical trials
(RE-COVER, RE-MEDY) suggest a favorable risk-benefit
profile for dabigatran for the treatment of established
venous thromboembolism [42,43] and additional studies
are ongoing [44,45].
Thrombolytic agents
The ACCP currently carries a Grade 1B level of evidence
recommendation in support of thrombolytic administra-
tion to hemodynamically unstable patients with massive,
acute pulmonary embolism in the absence of absolute
contraindications[1],andwhilemostcliniciansagree,they
are often reluctant to pursue this course [46]. A summary
of the ACCP recommendations for administration of
thrombolytic therapy is outlined in Table 5. Thrombolytic
therapyisgenerallyadministeredbyperipheralintravenous
Table 4. Advantages of low molecular weight heparin over standard, unfractionated heparin*
1. Low molecular weight heparin is at least as effective as standard, unfractionated heparin.
2. In certain prophylactic settings, it is more effective than standard, unfractionated heparin**
3. No intravenous line needed with low molecular weight heparin.
†
4. More bioavailable than standard, unfractionated heparin; thus, generally no monitoring with low molecular weight heparin.
†
5. Low molecular weight heparin facilitates outpatient therapy.
6. Better quality of life, fewer nosocomial complications with low molecular weight heparin.
7. Less heparin-induced thrombocytopenia with low molecular weight heparin.
*Disadvantages include the need to dose adjust low  molecular  weight  heparin for renal insufficiency.
**Examples include total hip/knee replacement, acute stroke with hemiplegia, spinal cord injury.
†
or any time absorption or therapeutic levels are questioned.
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Monitoring anti-Xa levels while on low  molecular  weight  heparin can be considered if renal function is changing, with long-term use in pregnancy, in extremes
of body weight,infusion. A number of intrapulmonary arterial/intraem-
bolic approaches have been evaluated, including intraem-
bolic thrombolytic delivery, suction, rheolytic and
rotationaldevices,and ultrasound-enhancedthrombolysis
[47-55]. As with systemic thrombolysis and surgical
embolectomy, clinical trial data for percutaneous catheter
intervention (with or without thrombolytics) for acute
pulmonary embolism are insufficient to formulate strong
recommendations. The potential for an aggressive
approachwithperhapsalowerbleedingriskthansystemic
thrombolysis makes these approaches attractive. Overall
success rates range from 67% to 100% [47] but studies
suffer from significant potential reporting bias. At present,
local expertise and familiarity with a particular device
should guide the clinician when a catheter-based proce-
dure appears indicated.
Risk stratification in acute pulmonary embolism
In recent years there have been many advances in risk
stratification of pulmonary embolism to ensure that the
appropriate treatment is given.
There has been increasing interest in identifying low-risk
patients with pulmonary embolism who could be
potential candidates for outpatient treatment or a brief
hospital stay. A clinical score for predicting early mortality
in patients with pulmonary embolism has recently been
described by Aujesky and associates [56]. The score was
derived from a large hospital data base and has been
prospectively validated in several independent cohorts
[56,57]. Higher scores were associated with advanced age,
male sex, number of comorbid conditions and certain
clinical abnormalities. However, patients with shock were
excluded and the study did not risk stratify for more
aggressive approaches.
A challenging dilemma lies with the patient who is not
hemodynamically compromised per se, but in whom
there appears to be a high risk of decompensation. Stable
patients with an abnormal right ventricle and normal
blood pressure (“submassive pulmonary embolism”)
may fall into this category.
In hemodynamically stable patients with right ventricular
dysfunction, Konstantinides and associates [58] demon-
strated that patients who received tissue plasminogen
activator were significantly less likely to deteriorate
clinically than those who received placebo (11% versus
25%) although there was no difference in all-cause
mortality. However, treating physicians were allowed to
break protocol and administer thrombolytics if they
believed that a patient was doing poorly, and there was a
high rate of rescue thrombolysis. A number of studies offer
compelling arguments that right ventricular dysfunction is
an important marker for mortality [59,60]. In the ICOPER
registry, the in-hospital mortality of patients with right
ventricular dysfunction on echocardiography was 18%,
although patients with shock were not analyzed separately
[61]. The potential mortality benefit of thrombolytic
therapy in pulmonary embolism patients with right
ventricular dysfunction and preserved systemic arterial
blood pressure should be carefully considered, although
large randomized trials have not been completed. As noted
subsequently, other factors may aid in the decision to
proceed with such aggressive approaches.
Itwouldbeidealtoexploretheimpactofvariousdegreesof
right ventricular enlargement and dysfunction in pulmon-
ary embolism. It is unlikely that mild right ventricular
dysfunction would result in death in a pulmonary embo-
lism patient in the absence of recurrent emboli – more
extreme right ventricular dysfunction is more likely to.
While the electrocardiogram has generally been deemed
less useful than echocardiography in risk stratification, it
may reveal T-wave inversionor a pseudoinfarctionpattern
(Qr) in the anterior precordial leads. This suggests right
ventricular dilation and dysfunction, which can be
integrated into risk stratification decisions [62]. Finally,
recent data suggest that mortality due to acute pulmonary
Table 5. A Synopsis of Key Thrombolytic Therapy Recommendations from the 8th ACCP Consensus [1]*
1. All pulmonary embolism patients should undergo rapid risk stratification (Grade 1C).
†
2. With hemodynamic compromise, thrombolytic therapy is recommended, unless there are major contraindications due to bleeding risk (Grade 1B).
‡
3. In selected high-risk patients without hypotension, and with a low risk of bleeding, administration of thrombolytic therapy is suggested (Grade 2B).
4. In acute pulmonary embolism, when a thrombolytic agent is used, peripheral vein administration rather than direct pulmonary artery infusion is
recommended (Grade 1B).
5. In patients with acute pulmonary embolism, we recommend use of thrombolytic regimens with short infusion times (e.g. a 2-h infusion) over those with
prolonged infusion times (e.g. a 24-h infusion) (Grade 1B).
*The decision to use thrombolytics depends on the clinician’s assessment of PE severity, prognosis, and bleeding risk.
†Grade 1 denotes a strong recommendation, and grade 2 a weak recommendation (“suggestion”). Level A would be based upon high-quality
randomized trial data, while B indicates moderate-quality evidence, and C low- or very low-quality evidence.
‡Unstable hemodynamics is the clearest indication for thrombolytic therapy. It is controversial as to whether hypotension caused by PE, in the absence
of the need for pressors, constitutes a clear indication for thrombolysis. The need for pressors mandates strong consideration for thrombolytics.
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thrombosis,sothatevaluationofthelegsaspartoftherisk
stratification protocol in acute pulmonary embolism
should be considered [30]. High levels of BNP, pro-BNP,
and cardiac troponins (both T and I) have been associated
with a greater risk of death in patients with pulmonary
embolism [63,64]. A meta-analysis of 1,985 pulmonary
embolism patients from 20 studies showed that any
elevation in troponin level confers a five-fold increase in
short-term mortality [65]. Troponin levels predict out-
come not only for pulmonary embolism patients in shock
but also for those who are hemodynamically stable at
presentation. Again, lack of randomization and differing
definitions for significant elevation of biomarkers prevent
firm conclusions. Factors to be considered for risk
stratification are shown in Table 6. The American Heart
Association Scientific Statement published in March 2011
offers an excellent literature review and presents a
compelling rationale for risk stratification of acute
pulmonary embolism patients [66].
Risk stratification in massive
pulmonary embolism
Patients with pulmonary embolism may present with
circulatory collapse or respiratory failure; in such extreme
settings, risk stratification may simply consist of proof of
pulmonary embolism and documentation of significant
hypotension. Treatment combines symptomatic inter-
ventions to reverse hemodynamic instability and respi-
ratory failure and treatments designed to decrease
pulmonary vascular obstruction rapidly [6,27]. Transfer
to the intensive care unit should be considered in any
pulmonary embolism patient with unstable vital signs,
significant hypoxemia, or evidence of unstable hemo-
dynamics. Oxygen and intubation with mechanical
ventilation are instituted as clinically indicated and
administered based upon oxygen saturation/arterial
blood gas assessment; the potential detrimental effects
of mechanical ventilation on right heart function must
be realized.
The traditional first-line treatment for hypotension is
volume expansion. Evidence from animal experiments
suggests that, in cases of pulmonary hypertension, this
may increase myocardial oxygen consumption, resulting
in right ventricular ischemia and worsening right ventri-
cular function. Nonetheless, fluid loading may improve
the hemodynamic status of patients with massive pul-
monary embolism [67].
Vasopressor therapy is still used in the setting of massive
pulmonary embolism. However, in experimental animal
models with massive pulmonary embolism and severe
hypotension, the vasopressor isoproterenol did not prove
beneficial and may in fact be detrimental [68,69]. In
contrast, norepinephrine improved right ventricular func-
tion in animal experiments, increasing systemic arterial
pressure over a wide range of blood pressure and right
ventricular afterloads, suggesting that its effects were not
limited to the subset of animals with profound hypoten-
sion [70]. This suggests that norepinephrine may be worth
considering in patients with massive pulmonary embo-
lism. Evidence relating to the effects of epinephrine in
patients with massive pulmonary embolism and shock
arises from small case series or single case reports in which
patients also received thrombolytic therapy and other
vasopressors [71].
Embolectomy and vena caval filter placement
No clear guidelines can be offered for pulmonary
embolectomy. It is reasonable to consider it in patients
with proven massive pulmonary embolism and hemody-
namic instability, particularly when thrombolytic therapy
has failed or is contraindicated [1,72,73]. Because these
patients are very compromised, the risk of death may be
high withthisapproach.A surgical approachissometimes
considered when there are right heart thrombi, with or
without paradoxical embolism, but no data from rando-
mized trials are available; thrombolysis is also commonly
considered in such cases.
The primary indications for inferior vena caval filter
placement include contraindications to anticoagulation,
major bleeding complications during anticoagulation,
and recurrent embolism while on therapeutic antic-
oagulation [1]. Filters are sometimes placed, in the case
of massive pulmonary embolism, when it is believed that
additional emboli might be lethal, either with or without
Table 6. Factors to consider when risk-stratifying patients with acute pulmonary  embolism
1. Vital signs (excessive tachycardia/tachypnea, hypotension – unstable hemodynamics is the clearest indication for thrombolytic therapy).
2. Echocardiography (right ventricle enlargement/hypokinesis).
3. Biomarkers (troponin/brain natriuretic peptide).
4. Oxygenation.
5. Clot burden (lung and legs).
6. Comorbid disease/cardiopulmonary reserve.
7. Bleeding risk.
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based on clinical trial data and more data should be
acquired. While filters are effective in reducing the
incidence of pulmonary embolism, they have been
shown to increase the incidence of deep venous throm-
bosisandhavenotbeenshowntoincreaseoverallsurvival
[74]. Retrieval is feasible after many months and removal
approximately one year after placement has beenreported
[75,76] but more data are needed to guide this practice.
Recommendations for the use of vena caval filters have
recently been published [76].
Conclusions
In summary, acute pulmonary embolism is a potentially
fatal disease, and clinicians should be aware of potential
risk factors, and the typical and more unusual presenta-
tions. Anticoagulation is the standard care for stable
p a t i e n t sa n ds h o u l db ec o n s i d e r e de v e np r i o rt o
diagnosis of pulmonary embolism if there is a strong
suspicion of pulmonary embolism and the risk of
bleeding is deemed low. The presence of unstable
hemodynamics is a strong indication for thrombolytic
therapy. When anticoagulation is contraindicated, an
inferior vena caval filter should be placed. Patients
should be risk-stratified and, when appropriate, con-
sidered for more aggressive therapy. Given this complex-
ity, risk stratification has become a crucial cornerstone in
approaching therapy, but it is still evolving and more
data are needed.
Abbreviations
BNP, brain natriuretic peptide; COPD, chronic obstruc-
tive pulmonary disease; CTA, computed tomographic
angiography; VQ, ventilation/perfusion.
Competing interests
The author has received research grants from sanofi
Aventis and Bayer, and has received financial compensa-
tion for consulting from sanofi Aventis and Bayer in the
past year and prior. He has received consulting and
lecturingfeesmorethanoneyearagofromEKOS,Bacchus,
Biolex, and Bristol-Myers Squibb prior to one year ago.
References
1. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE,
Comerota AJ: Antithrombotic therapy for venous throm-
boembolic disease: American College of Chest Physicians
Evidence-Based Clinical Practice Guidelines (8th Edition).
Chest 2008, 133:454S-545S.
2. Dalen JE: Pulmonary embolism: what have we learned since
Virchow? Natural history, pathophysiology, and diagnosis.
Chest 2002, 122:1440-56.
3. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O’Fallon WM,
Melton LJ: Trends in the incidence of deep vein thrombosis and
pulmonary embolism: a 25-year population-based study. Arch.
Intern. Med 1998, 158:585-93.
4. Sandler DA, Martin JF: Autopsy proven pulmonary embolism
in hospital patients: are we detecting enough deep vein
thrombosis? J R Soc Med 1989, 82:203-5.
F1000 Factor 8
Evaluated by Victor Tapson 24 April 2012
5. Morgenthaler TI, Ryu JH: Clinical characteristics of fatal
pulmonary embolism in a referral hospital. Mayo Clin. Proc
1995, 70:417-24.
F1000 Factor 6
Evaluated by Victor Tapson 24 April 2012
6. Tapson VF: Acute pulmonary embolism. N. Engl. J. Med 2008,
358:1037-52.
7. Anderson FA, Spencer FA: Risk factors for venous thromboem-
bolism. Circulation 2003, 107:I9-16.
F1000 Factor 6
Evaluated by Victor Tapson 24 April 2012
8. Fedullo PF, Tapson VF: Clinical practice. The evaluation of
suspected pulmonary embolism. N. Engl. J. Med 2003, 349:
1247-56.
9. Susec O, Boudrow D, Kline JA: The clinical features of acute
pulmonary embolism in ambulatory patients. Acad Emerg Med
1997, 4:891-7.
F1000 Factor 6
Evaluated by Victor Tapson 24 April 2012
10. Le Gal G, Testuz A, Righini M, Bounameaux H, Perrier A:
Reproduction of chest pain by palpation: diagnostic accuracy
in suspected pulmonary embolism. BMJ 2005, 330:452-3.
F1000 Factor 6
Evaluated by Victor Tapson 24 April 2012
11. den Exter PL, Hooijer J, Dekkers OM, Huisman MV: Risk of recurrent
venousthromboembolismandmortalityinpatientswithcancer
incidentallydiagnosedwithpulmonaryembolism:acomparison
with symptomatic patients. J. Clin. Oncol 2011, 29:2405-9.
F1000 Factor 6
Evaluated by Victor Tapson 24 April 2012
Table 7. Key points in diagnosis/treatment of pulmonary embolism
1. Therapy for acute pulmonary embolism should be initiated if the clinical suspicion is high and the perceived bleeding risk is low.
2. As anticoagulation is initiated and pulmonary embolism is diagnosed, risk stratification should be considered.
3. Depending on the scenario, more aggressive treatment with thrombolytic therapy or embolectomy can be considered.
4. There is now a large body of evidence from large randomized comparisons that unfractionated heparin, low molecular weight heparin and fondaparinux
are all safe and effective approaches to initial anticoagulation.
5. Low molecular weight heparin and fondaparinux are easier to administer, do not require monitoring, and are backed by a substantial evidencebase in the
modern era.
6. Documented venous thromboembolism in patients with transient risk factors should be treated for 3 to 6 months, but more extended treatment is
appropriate when significant risk factors persist, when venous thromboembolism is idiopathic, or when venous thromboembolism is recurrent.
7. Bleeding risk should also be considered.
8. Inferior vena caval filter placement should be undertaken if anticoagulation is contraindicated due to bleeding.
9. Evidence-based guidelines continue to be refined based upon new clinical trial data. New anticoagulants are on the horizon.
Page 8 of 11
(page number not for citation purposes)
F1000 Medicine Reports 2012, 4:9 http://f1000.com/reports/m/4/912. Afzal A, Noor HA, Gill SA, Brawner C, Stein PD: Leukocytosis in
acute pulmonary embolism. Chest 1999, 115:1329-32.
13. Wells PS, Anderson DR, Rodger M, Stiell I, Dreyer JF, Barnes D,
Forgie M, Kovacs G, Ward J, Kovacs MJ: Excluding pulmonary
embolism at the bedside without diagnostic imaging:
management of patients with suspected pulmonary embo-
lism presenting to the emergency department by using a
simple clinical model and d-dimer. Ann. Intern. Med 2001,
135:98-107.
14. Aujesky D, Roy P, Guy M, Cornuz J, Sanchez O, Perrier A:
Prognostic value of D-dimer in patients with pulmonary
embolism. Thromb. Haemost 2006, 96:478-82.
15. Scridon T, Scridon C, Skali H, Alvarez A, Goldhaber SZ, Solomon SD:
Prognostic significance of troponin elevation and right
ventricular enlargement in acute pulmonary embolism. Am.
J. Cardiol 2005, 96:303-5.
16. Pruszczyk P, Kostrubiec M, Bochowicz A, Styczyński G, Szulc M,
Kurzyna M, Fijałkowska A, Kuch-Wocial A, Chlewicka I, Torbicki A:
N-terminal pro-brain natriuretic peptide in patients with
acute pulmonary embolism. Eur. Respir. J 2003, 22:649-53.
17. Stein PD, Terrin ML, Hales CA, Palevsky HI, Saltzman HA,
Thompson BT, Weg JG: Clinical, laboratory, roentgenographic,
and electrocardiographic findings in patients with acute
pulmonary embolism and no pre-existing cardiac or pulmon-
ary disease. Chest 1991, 100:598-603.
F1000 Factor 6
Evaluated by Victor Tapson 24 April 2012
18. Rodger M, Makropoulos D, Turek M, Quevillon J, Raymond F, Rasuli P,
Wells PS: Diagnostic value of the electrocardiogram in
suspectedpulmonaryembolism.Am. J.Cardiol2000,86:807-9,A10.
19. Johson JC, Flowers NC, Horan LG: Unexplained atrial flutter: a
frequent herald of pulmonary embolism. Chest 1971, 60:29-34.
F1000 Factor 6
Evaluated by Victor Tapson 24 April 2012
20. Worsley DF, Alavi A, Aronchick JM, Chen JT, Greenspan RH,
Ravin CE: Chest radiographic findings in patients with acute
pulmonary embolism: observations from the PIOPED Study.
Radiology 1993, 189:133-6.
21. Casazza F, Bongarzoni A, Capozi A, Agostoni O: Regional right
ventricular dysfunction in acute pulmonary embolism and
right ventricular infarction. Eur J Echocardiogr 2005, 6:11-4.
F1000 Factor 6
Evaluated by Victor Tapson 24 April 2012
22. Kline JA, Courtney DM, Kabrhel C, Moore CL, Smithline HA,
Plewa MC, Richman PB, O’Neil BJ, Nordenholz K: Prospective
multicenter evaluation of the pulmonary embolism rule-out
criteria. J. Thromb. Haemost 2008, 6:772-80.
F1000 Factor 6
Evaluated by Victor Tapson 24 April 2012
23. Wicki J, Perneger TV, Junod AF, Bounameaux H, Perrier A: Assessing
clinical probability of pulmonary embolism in the emergency
ward: a simple score. Arch. Intern. Med 2001, 161:92-7.
F1000 Factor 6
Evaluated by Victor Tapson 24 April 2012
24. Le Gal G, Righini M, Roy P, Sanchez O, Aujesky D, Bounameaux H,
Perrier A: Prediction of pulmonary embolism in the emer-
gency department: the revised Geneva score. Ann. Intern. Med
2006, 144:165-71.
F1000 Factor 9
Evaluated by Andrew Polmear 14 Mar 2006, Paul Stein 15 Feb 2006
25. Klok FA, Mos ICM, Nijkeuter M, Righini M, Perrier A, Le Gal G,
Huisman MV: Simplification of the revised Geneva score for
assessing clinical probability of pulmonary embolism. Arch.
Intern. Med 2008, 168:2131-6.
26. Value of the ventilation/perfusion scan in acute pulmonary
embolism. Results of the prospective investigation of pul-
monary embolism diagnosis (PIOPED). The PIOPED Inves-
tigators. JAMA 263:2753-9.
27. Konstantinides S: Clinical practice. Acute pulmonary embo-
lism. N. Engl. J. Med 2008, 359:2804-13.
F1000 Factor 6
Evaluated by Victor Tapson 24 April 2012
28. Tillie-Leblond I, Marquette C, Perez T, Scherpereel A, Zanetti C,
Tonnel A, Remy-Jardin M: Pulmonary embolism in patients with
unexplained exacerbation of chronic obstructive pulmonary
disease: prevalence and risk factors. Ann. Intern. Med 2006,
144:390-6.
F1000 Factor 10
Evaluated by Paul Stein 10 Jul 2006
29. Stein PD, Fowler SE, Goodman LR, Gottschalk A, Hales CA, Hull RD,
Leeper KV, Popovich J, Quinn DA, Sos TA, Sostman HD, Tapson VF,
Wakefield TW, Weg JG, Woodard PK: Multidetector computed
tomography for acute pulmonary embolism. N. Engl. J. Med
2006, 354:2317-27.
30. Jiménez D, Aujesky D, Díaz G, Monreal M, Otero R, Martí D, Marín E,
Aracil E, Sueiro A, Yusen RD: Prognostic significance of deep vein
thrombosis in patients presenting with acute symptomatic
pulmonary embolism. Am. J. Respir. Crit. Care Med 2010, 181:983-91.
F1000 Factor 6
Evaluated by Victor Tapson 24 April 2012
31. Stein PD, Athanasoulis C, Alavi A, Greenspan RH, Hales CA,
Saltzman HA, Vreim CE, Terrin ML, Weg JG: Complications and
validity of pulmonary angiography in acute pulmonary
embolism. Circulation 1992, 85:462-8.
32. Stein PD, Chenevert TL, Fowler SE, Goodman LR, Gottschalk A,
Hales CA, Hull RD, Jablonski KA, Leeper KV, Naidich DP, Sak DJ,
Sostman HD, Tapson VF, Weg JG, Woodard PK: Gadolinium-
enhanced magnetic resonance angiography for pulmonary
embolism: a multicenter prospective study (PIOPED III). Ann.
Intern. Med 2010, 152:434-43, W142-3.
33. Büller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F,
Prins MH, Raskob G, van den Berg-Segers AEM, Cariou R,
Leeuwenkamp O, Lensing AWA: Subcutaneous fondaparinux
versus intravenous unfractionated heparin in the initial
treatment of pulmonary embolism. N. Engl. J. Med 2003,
349:1695-702.
F1000 Factor 6
Evaluated by Victor Tapson 24 April 2012
34. Bauer KA: Recent progress in anticoagulant therapy: oral
direct inhibitors of thrombin and factor Xa. J. Thromb. Haemost
2011, 9(Suppl 1):12-9.
35. Perzborn E, Strassburger J, Wilmen A, Pohlmann J, Roehrig S,
Schlemmer K, Straub A: In vitro and in vivo studies of the novel
antithrombotic agent BAY 59-7939–an oral, direct Factor Xa
inhibitor. J. Thromb. Haemost 2005, 3:514-21.
36. Wong PC, Crain EJ, Xin B, Wexler RR, Lam PYS, Pinto DJ,
Luettgen JM, Knabb RM: Apixaban, an oral, direct and highly
selective factor Xa inhibitor: in vitro, antithrombotic and
antihemostatic studies. J. Thromb. Haemost 2008, 6:820-9.
37. Samama MM: The mechanism of action of rivaroxaban–an oral,
direct Factor Xa inhibitor–compared with other anticoagu-
lants. Thromb. Res 2011, 127:497-504.
38. Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H,
Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A,
Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A,
Davidson BL, Piovella F, Schellong S: Oral rivaroxaban for
symptomatic venous thromboembolism. N. Engl. J. Med 2010,
363:2499-510.
F1000 Factor 6
Evaluated by Victor Tapson 24 April 2012
Page 9 of 11
(page number not for citation purposes)
F1000 Medicine Reports 2012, 4:9 http://f1000.com/reports/m/4/939. ClinicalTrials.gov. Oral Direct Factor Xa Inhibitor Rivaroxaban In
Patients With Acute Symptomatic Pulmonary Embolism With Or
Without Symptomatic Deep-Vein Thrombosis: Einstein-PE Evaluation.
Available at: http://clinicaltrials.gov/ct2/show/NCT00439777. Updated
July 10, 2011. Accessed October 19, 2011.
40. Stangier J: Clinical pharmacokinetics and pharmacodynamics
of the oral direct thrombin inhibitor dabigatran etexilate. Clin
Pharmacokinet 2008, 47:285-95.
41. United States Food and Drug Administration. FDA approves Pradaxa
to prevent stroke in people with atrial fibrillation [press release].
October 19, 2010. Available at: http://www.fda.gov/NewsEvents/
Newsroom/PressAnnouncements/ucm230241.htm. Accessed July 28,
2011.
F1000 Factor 6
Evaluated by Victor Tapson 24 April 2012
42. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S,
Eriksson H, Baanstra D, Schnee J, Goldhaber SZ: Dabigatran versus
warfarin in the treatment of acute venous thromboembo-
lism. N. Engl. J. Med 2009, 361:2342-52.
F1000 Factor 6
Evaluated by Victor Tapson 24 April 2012
43. Schulman S, Eriksson H, Goldhaber SZ, Lord Kakkar AK, Kearon C,
Kvamme AM, Mismetti P, Schellong S, Schnee J: Dabigatran or
warfarin for extended maintenance therapy of venous
thromboembolism. J Thromb Haemost. 2011, 9(Suppl 2):731.
Abstract O-TH-033.
44. ClinicalTrials.gov. Efficacy and Safety of Dabigatran Compared to
Warfarin for 6 Month Treatment of Acute Symptomatic Venous
Thromboembolism. Available at: http://clinicaltrials.gov/ct2/show/
NCT00329238. Updated February 10, 2011. Accessed June 3, 2011.
45. ClinicalTrials.gov. Twice-daily Oral Direct Thrombin Inhibitor Dabi-
gatran Etexilate in the Long Term Prevention of Recurrent
Symptomatic VTE. Available at: http://clinicaltrials.gov/ct2/show/
NCT00558259. Updated May 4, 2011. Accessed June 3, 2011.
46. Witty LA, Krichman A, Tapson VF: Thrombolytic therapy
for venous thromboembolism: Utilization by practicing
pulmonologists. Arch Intern Med 1994, 154:1601-4.
47. Kucher N: Catheter embolectomy for acute pulmonary
embolism. Chest 2007, 132:657-63.
F1000 Factor 6
Evaluated by Victor Tapson 24 April 2012
48. Tapson VF, Gurbel PA, Witty LA, Pieper KS, Stack RS: Pharmaco-
mechanical thrombolysis of experimental pulmonary emboli.
Rapid low-dose intraembolic therapy. Chest 1994, 106:1558-62.
49. Greenfield LJ, Proctor MC, Williams DM, Wakefield TW: Long-term
experience with transvenous catheter pulmonary embolect-
omy. J. Vasc. Surg 1993, 18:450-7; discussion 457-8.
50. Schmitz-Rode T, Janssens U, Duda SH, Erley CM, Günther RW:
Massive pulmonary embolism: percutaneous emergency
treatment by pigtail rotation catheter. J. Am. Coll. Cardiol 2000,
36:375-80.
51. Müller-Hülsbeck S, Brossmann J, Jahnke T, Grimm J, Reuter M,
Bewig B, Heller M: Mechanical thrombectomy of major and
massive pulmonary embolism with use of the Amplatz
thrombectomy device. Invest Radiol 2001, 36:317-22.
52. Fava M, Loyola S, Huete I: Massive pulmonary embolism:
treatment with the hydrolyser thrombectomy catheter.
J Vasc Interv Radiol 2000, 11:1159-64.
53. Reekers JA, Baarslag HJ, Koolen MGJ, van Delden O, van Beek EJR:
Mechanical thrombectomy for early treatment of massive
pulmonary embolism. Cardiovasc Intervent Radiol 26:246-50.
54. Margheri M, Vittori G, Vecchio S, Chechi T, Falchetti E, Spaziani G,
Giuliani G, Rovelli S, Consoli L, Biondi Zoccai GGL: Early and long-
term clinical results of AngioJet rheolytic thrombectomy in
patients with acute pulmonary embolism. Am. J. Cardiol 2008,
101:252-8.
55. Chamsuddin A, Nazzal L, Kang B, Best I, Peters G, Panah S,
Martin L, Lewis C, Zeinati C, Ho JW, Venbrux AC: Catheter-
directed thrombolysis with the Endowave system in the
treatment of acute massive pulmonary embolism: a retro-
spective multicenter case series. J Vasc Interv Radiol 2008,
19:372-6.
56. Aujesky D, Perrier A, Roy P, Stone RA, Cornuz J, Meyer G,
Obrosky DS, Fine MJ: Validation of a clinical prognostic model
to identify low-risk patients with pulmonary embolism.
J. Intern. Med 2007, 261:597-604.
F1000 Factor 6
Evaluated by Victor Tapson 24 April 2012
57. Aujesky D, Obrosky DS, Stone RA, Auble TE, Perrier A, Cornuz J,
Roy P, Fine MJ: Derivation and validation of a prognostic model
for pulmonary embolism. Am. J. Respir. Crit. Care Med 2005,
172:1041-6.
58. Konstantinides S, Geibel A, Heusel G, Heinrich F, Kasper W:
Heparin plus alteplase compared with heparin alone in
patients with submassive pulmonary embolism. N. Engl. J.
Med 2002, 347:1143-50.
F1000 Factor 6
Evaluated by Victor Tapson 24 April 2012
59. Goldhaber SZ, Haire WD, Feldstein ML, Miller M, Toltzis R, Smith JL,
Taveira da Silva AM, Come PC, Lee RT, Parker JA: Alteplase versus
heparin in acute pulmonary embolism: randomised trial
assessing right-ventricular function and pulmonary perfusion.
Lancet 1993, 341:507-11.
F1000 Factor 6
Evaluated by Victor Tapson 24 April 2012
60. Ribeiro A, Lindmarker P, Juhlin-Dannfelt A, Johnsson H, Jorfeldt L:
Echocardiography Doppler in pulmonary embolism: right
ventricular dysfunction as a predictor of mortality rate. Am.
Heart J 1997, 134:479-87.
F1000 Factor 6
Evaluated by Victor Tapson 24 April 2012
61. Goldhaber SZ, Visani L, Rosa M de: Acute pulmonary
embolism: clinical outcomes in the International Coopera-
tive Pulmonary Embolism Registry (ICOPER). Lancet 1999,
353:1386-9.
F1000 Factor 6
Evaluated by Victor Tapson 24 April 2012
62. Pruszczyk P, Bochowicz A, Torbicki A, Szulc M, Kurzyna M,
Fijałkowska A, Kuch-Wocial A: Cardiac troponin T monitoring
identifies high-risk group of normotensive patients with acute
pulmonary embolism. Chest 2003, 123:1947-52.
F1000 Factor 6
Evaluated by Victor Tapson 24 April 2012
63. Kostrubiec M, Pruszczyk P, Bochowicz A, Pacho R, Szulc M,
Kaczynska A, Styczynski G, Kuch-Wocial A, Abramczyk P,
Bartoszewicz Z, Berent H, Kuczynska K: Biomarker-based risk
assessment model in acute pulmonary embolism. Eur. Heart J
2005, 26:2166-72.
64. Becattini C, Vedovati MC, Agnelli G: Prognostic value of
troponins in acute pulmonary embolism: a meta-analysis.
Circulation 2007, 116:427-33.
F1000 Factor 8
Evaluated by Jane Freedman 07 Aug 2007
65. Kucher N, Walpoth N, Wustmann K, Noveanu M, Gertsch M: QR in
V1–an ECG sign associated with right ventricular strain and
adverse clinical outcome in pulmonary embolism. Eur. Heart J
2003, 24:1113-9.
F1000 Factor 6
Evaluated by Victor Tapson 24 April 2012
Page 10 of 11
(page number not for citation purposes)
F1000 Medicine Reports 2012, 4:9 http://f1000.com/reports/m/4/966. Jaff MR, McMurtry MS, Archer SL, Cushman M, Goldenberg N,
Goldhaber SZ, Jenkins JS, Kline JA, Michaels AD, Thistlethwaite P,
Vedantham S, White RJ, Zierler BK: Management of massive and
submassive pulmonary embolism, iliofemoral deep vein
thrombosis, and chronic thromboembolic pulmonary hyper-
tension: a scientific statement from the American Heart
Association. Circulation 2011, 123:1788-830.
F1000 Factor 6
Evaluated by Victor Tapson 24 April 2012
67. Mercat A, Diehl JL, Meyer G, Teboul JL, Sors H: Hemodynamic
effects of fluid loading in acute massive pulmonary embolism.
Crit. Care Med 1999, 27:540-4.
F1000 Factor 6
Evaluated by Victor Tapson 24 April 2012
68. Layish DT, Tapson VF: Pharmacologic hemodynamic support in
massive pulmonary embolism. Chest 1997, 111:218-24.
69. McDonald IG, Hirsh J, Hale GS, Cade JF, McCarthy RA: Isoproter-
enol in massive pulmonary embolism: haemodynamic and
clinical effects. Med. J. Aust 1968, 2:201-5.
F1000 Factor 6
Evaluated by Victor Tapson 24 April 2012
70. Ghignone M, Girling L, Prewitt RM: Volume expansion versus
norepinephrine in treatment of a low cardiac output
complicating an acute increase in right ventricular afterload
in dogs. Anesthesiology 1984, 60:132-5.
F1000 Factor 6
Evaluated by Victor Tapson 24 April 2012
71. Boulain T, Lanotte R, Legras A, Perrotin D: Efficacy of epinephrine
therapy in shock complicating pulmonary embolism. Chest
1993, 104:300-2.
F1000 Factor 6
Evaluated by Victor Tapson 24 April 2012
72. Leacche M, Unic D, Goldhaber SZ, Rawn JD, Aranki SF, Couper GS,
Mihaljevic T, Rizzo RJ, Cohn LH, Aklog L, Byrne JG: Modern surgical
treatment of massive pulmonary embolism: results in 47
consecutive patients after rapid diagnosis and aggressive
surgical approach. J. Thorac. Cardiovasc. Surg 2005, 129:1018-23.
F1000 Factor 6
Evaluated by Victor Tapson 24 April 2012
73. Meyer G, Tamisier D, Sors H, Stern M, Vouhé P, Makowski S,
Neveux JY, Leca F, Even P: Pulmonary embolectomy: a 20-year
experience at one center. Ann. Thorac. Surg 1991, 51:232-6.
74. Decousus H, Leizorovicz A, Parent F, Page Y, Tardy B, Girard P,
Laporte S, Faivre R, Charbonnier B, Barral FG, Huet Y, Simonneau G:
A clinical trial of vena caval filters in the prevention of
pulmonary embolism in patients with proximal deep-vein
thrombosis. Prévention du Risque d’Embolie Pulmonaire
par Interruption Cave Study Group. N. Engl. J. Med 1998, 338:
409-15.
F1000 Factor 6
Evaluated by Victor Tapson 24 April 2012
75. Mismetti P, Rivron-Guillot K, Quenet S, Décousus H, Laporte S,
Epinat M, Barral FG: A prospective long-term study of
220 patients with a retrievable vena cava filter for secondary
prevention of venous thromboembolism. Chest 2007, 131:
223-9.
F1000 Factor 6
Evaluated by Victor Tapson 24 April 2012
76. Kaufman JA, Kinney TB, Streiff MB, Sing RF, Proctor MC, Becker D,
Cipolle M, Comerota AJ, Millward SF, Rogers FB, Sacks D,
Venbrux AC: Guidelines for the use of retrievable and
convertible vena cava filters: report from the Society of
Interventional Radiology multidisciplinary consensus confer-
ence. J Vasc Interv Radiol 2006, 17:449-59.
F1000 Factor 6
Evaluated by Victor Tapson 24 April 2012
Page 11 of 11
(page number not for citation purposes)
F1000 Medicine Reports 2012, 4:9 http://f1000.com/reports/m/4/9